Abstract:OBJECTIVE:Acute monocytic leukemia (AML)-M5 is the common type of acute myeloid leukemias in children. Studies have shown that there are abundant lipopolysaccharide (LPS) receptor (designated as CD14) molecules on the cell membrane of M5 cells and they play an important role in the diagnosis of M5, since they can be recognized and bound by mouse-anti-human CD14 monoclonal antibody (McAb). However, mouse-originated antibodies are largely not suitable for clinical application due to the severe side effects, thus "humanized antibody" is desired. As the first step for developing humanized antibody, the construction and expression of single chain antibody (scFv) with functional protein are necessary. The present study aimed to express ZCH-7-2F9 ScFv (scFv(2F9)) in eukaryotic cells and obtain the scFv(2F9) protein with a high biological activity.METHODS:Four primers were synthesized to construct the eukaryotic expressional vector, which included SfiI and EcoRI enzyme cleaving site, 6 x His and stop code TGA sequences. scFv(2F9) gene was amplified through splicing by overlap extension (SOE) using the high fidelity Taq polymerase. Positive recombinants (pSectag2A/scFv(2F9)) were identified through enzyme cleaving and sequenced before expression and were transformed into Chinese hamster ovary (CHO) cells for expression. Western-Blot and flow cytometry (FCM) were carried out to determine the relative molecular mass (Mr) and binding activity of scFv(2F9).RESULTS:The cloned scFv(2F9) gene was identified to be functional by sequencing and expressing. The interested protein could be detected in the culture supernatant of transformed CHO cells with an Mr of 31 000. The blocking test showed that the positive cell percentages, the mean fluorescence intensity (MFI) and the peak of channel (peak Ch) were reduced by 90.02%, 63.30% and 63.38%, respectively after blocking with scFv(2F9), while those were 4.55%, 10.09% and 5.02% after blockage using the supernatant from the CHO cells transfected with blanked vector pSectag2A.CONCLUSIONS:The scFv(2F9) against human CD14 antigen was successfully expressed in eukaryotic cells and showed a high biological activity, which may be useful for the further studies on its humanized antibodies.

The Construction and Expression of A Novel Chimeric Anti-Dr5 Antibody

[Construction and expression of anti-tumor necrosis factor related apoptosis-inducing ligand receptor death receptor 5 chimeric antibody in eukaryotic cells]

Characterization of a Novel Anti-DR5 Monoclonal Antibody WD1 with the Potential to Induce Tumor Cell Apoptosis

Successful construction and massive expression of a novel Anti-CD19 human-mouse chimeric antibody Hm2E8b.

A Novel Fully Human Agonistic Single Chain Fragment Variable Antibody Targeting Death Receptor 5 with Potent Antitumor Activity in Vitro and in Vivo

Construction, Expression, and Characterization of a Novel Human-Mouse Chimeric Antibody, Hm3A4: A Potential Therapeutic Agent for B and Myeloid Lineage Leukemias.

The Preparation and Tumor Cell Apoptosis-Inducing Activity Assay of Anti-Human DR5 Single-Chain Antibody

Analysis of aDR5scFv with Specific Identification and Function.

The Characteristic of an Anti-Human DR5 Antibody A6

Construction and Expression of a Human/mouse Chimeric CD19 Monoclonal Antibody: Successful Modification of a Murine IgM to a Chimeric IgG.

Preparation and Characterization of A Set of Monoclonal Antibodies to Trail and Trail Receptors Dr4, Dr5, Dcr1, and Dcr2

Preparation and enhanced eukaryotic expression of anti-human CD40 antibodies

Tumor-cell Specific Cytotoxic Activity of LBY135, a Novel Anti- DR5 Agonistic Antibody

Structural Basis of LaDR5, a Novel Agonistic Anti-Death Receptor 5 (DR5) Monoclonal Antibody, to Inhibit DR5/TRAIL Complex Formation

Preparation, Characterization, and Activity Analysis of Monoclonal Antibodies Against Human Death Receotor 5

The design, construction and function of a new chimeric anti-CD20 antibody.

Construction and Characterization of a High-Affinity Humanized SM5-1 Monoclonal Antibody.

[Construction and Expression of Human-Mouse Chimeric Antibody Against Human CD40].

Design, Expression, Purification and Characterization of the Recombinant Immunotoxin 4D5 Scfv-Trail

Construction and Expression of Single-Chain Antibody Derived from a New Clone of Monoclonal Antibody Against Human CD14 in CHO Cells

[Eukaryotic Expression and Determination of ZCH-7-2F9 Single Chain Antibody Against Human CD14].